A detailed history of Aviva PLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Aviva PLC holds 124,840 shares of VRTX stock, worth $51 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
124,840
Previous 121,917 2.4%
Holding current value
$51 Million
Previous $57.1 Million 1.6%
% of portfolio
0.16%
Previous 0.17%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $1.34 Million - $1.48 Million
2,923 Added 2.4%
124,840 $58.1 Million
Q2 2024

Aug 02, 2024

BUY
$392.81 - $485.53 $9.39 Million - $11.6 Million
23,916 Added 24.4%
121,917 $57.1 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $11.8 Million - $12.9 Million
-28,982 Reduced 22.82%
98,001 $41 Million
Q4 2023

Feb 09, 2024

BUY
$343.0 - $410.68 $5.95 Million - $7.13 Million
17,357 Added 15.83%
126,983 $51.7 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $2.98 Million - $3.2 Million
8,816 Added 8.75%
109,626 $38.1 Million
Q2 2023

Aug 10, 2023

SELL
$314.42 - $351.91 $17.5 Million - $19.6 Million
-55,572 Reduced 35.54%
100,810 $35.5 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $1.17 Million - $1.33 Million
4,121 Added 2.71%
156,382 $49.3 Million
Q4 2022

Feb 09, 2023

SELL
$285.76 - $321.48 $5.36 Million - $6.03 Million
-18,744 Reduced 10.96%
152,261 $44 Million
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $6.52 Million - $7.28 Million
-23,816 Reduced 12.22%
171,005 $49.5 Million
Q2 2022

Aug 04, 2022

BUY
$234.96 - $292.55 $11.1 Million - $13.8 Million
47,073 Added 31.86%
194,821 $54.9 Million
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $12 Million - $14.2 Million
54,224 Added 57.98%
147,748 $38.6 Million
Q4 2021

Feb 10, 2022

SELL
$177.01 - $223.45 $1.53 Million - $1.93 Million
-8,617 Reduced 8.44%
93,524 $20.5 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $1.09 Million - $1.22 Million
6,025 Added 6.27%
102,141 $18.5 Million
Q2 2021

Aug 10, 2021

BUY
$187.49 - $221.1 $1.72 Million - $2.02 Million
9,156 Added 10.53%
96,116 $19.4 Million
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $86,120 - $100,384
-416 Reduced 0.48%
86,960 $18.7 Million
Q4 2020

Feb 10, 2021

BUY
$207.01 - $276.09 $731,780 - $975,978
3,535 Added 4.22%
87,376 $20.7 Million
Q3 2020

Nov 12, 2020

SELL
$255.65 - $303.1 $693,322 - $822,007
-2,712 Reduced 3.13%
83,841 $22.8 Million
Q2 2020

Aug 13, 2020

SELL
$225.48 - $295.8 $1.02 Million - $1.34 Million
-4,520 Reduced 4.96%
86,553 $25.1 Million
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $196,573 - $243,845
984 Added 1.09%
91,073 $21.7 Million
Q4 2019

Feb 10, 2020

SELL
$166.71 - $223.91 $84,021 - $112,850
-504 Reduced 0.56%
90,089 $19.7 Million
Q3 2019

Nov 12, 2019

SELL
$166.23 - $187.09 $589,784 - $663,795
-3,548 Reduced 3.77%
90,593 $15.3 Million
Q2 2019

Jul 30, 2019

SELL
$164.61 - $190.37 $385,187 - $445,465
-2,340 Reduced 2.43%
94,141 $17.3 Million
Q1 2019

May 14, 2019

BUY
$163.73 - $194.7 $28,652 - $34,072
175 Added 0.18%
96,481 $17.7 Million
Q4 2018

Feb 12, 2019

SELL
$151.91 - $192.21 $4.02 Million - $5.09 Million
-26,489 Reduced 21.57%
96,306 $16 Million
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $730,128 - $838,997
-4,353 Reduced 3.42%
122,795 $23.7 Million
Q2 2018

Aug 01, 2018

SELL
$145.72 - $169.96 $121,676 - $141,916
-835 Reduced 0.65%
127,148 $21.6 Million
Q1 2018

May 14, 2018

SELL
$151.6 - $177.13 $1.9 Million - $2.22 Million
-12,550 Reduced 8.93%
127,983 $20.9 Million
Q4 2017

Feb 13, 2018

SELL
$137.28 - $155.55 $2.41 Million - $2.73 Million
-17,545 Reduced 11.1%
140,533 $21.1 Million
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $506,604 - $554,860
3,420 Added 2.21%
158,078 $24 Million
Q2 2017

Aug 07, 2017

BUY
N/A
154,658
154,658 $19.9 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Aviva PLC Portfolio

Follow Aviva PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.